ARA- 290 16MG peptides

 ARA-290 – ARA 290 In Stock Now 

ARA-290, also called Cibinetide, is an engineered 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO). It is designed to activate the innate repair receptor (IRR) — a receptor complex (EPOR/CD131) that triggers anti-inflammatory and tissue-protective signaling without stimulating red blood-cell production (i.e., no erythropoietic effects). 

Primary research focuses on:

• Neuropathic pain relief (e.g., diabetic neuropathy)
• Tissue protection and inflammation modulation
• Potential metabolic benefits (small trials)
  but it remains investigational, not approved as a prescribed therapy. 

💉 Typical Research Dosing (Not Medical Advice)

📌 Clinical & Research Doses

Studies involving human subjects most commonly used subcutaneous injections once daily. Typical dosing protocols include: 

• In published clinical trials for type 2 diabetic neuropathy, subjects were given 4 mg SC daily for 28 days, self-administered under study conditions. 
• Many peptide reference guides also describe starting at lower doses before moving up to the typical 4 mg/day range. 

Important: There is no established medical guideline defining “correct” dosing for ARA-290 because it isn’t approved for standard medical use — all published dosing comes from research contexts.

📦 About the 16 mg Vial

A 16 mg vial of ARA-290 peptide simply contains 16 mg of lyophilized peptide powder intended for research or investigational use. Common reconstitution approaches (from peptide reference sources) broadly involve: 

• Adding bacteriostatic water or another sterile solvent to the vial
• Gently dissolving into solution
• Drawing up the desired dose into an insulin syringe for subcutaneous injection

For example, reconstituting a 16 mg vial with 2.0 mL of water gives ~8 mg/mL, meaning a 4 mg dose would be 0.50 mL (50 units) on a U-100 syringe.